HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cori Ann Sherwin Selected Research

fisogatinib

12/2019Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.
12/2019First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Cori Ann Sherwin Research Topics

Disease

3Neoplasms (Cancer)
01/2023 - 12/2019
1Nausea
12/2019
1Diarrhea
12/2019
1Hepatocellular Carcinoma (Hepatoma)
12/2019
1Vomiting
12/2019
1Disease Progression
12/2019

Drug/Important Bio-Agent (IBA)

2fisogatinibIBA
12/2019 - 12/2019
1Type 2 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 2)IBA
01/2023
1Phosphotransferases (Kinase)IBA
12/2019